Market Trends of Glucagon-like Peptide-1 (GLP-1) Agonists Industry
Dulaglutide Segment Occupied the Highest Market Share in the Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year
Dulaglutide drug held the highest share of about 45.8% in the Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year.
GLP1RAs are available internationally and are recommended for use when treatment escalation for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that reduces HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
Dulaglutide is fully funded for patients meeting special authority criteria in some countries. For instance, New Zealand guidelines recommend offering GLP1RAs to all patients with HbA1c levels above target, especially when GLP1RA use would provide additional reductions in cardiovascular risk and/or permit reduction or cessation of other therapies that contribute to weight gain or hypoglycemia.
Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, and the increasing prevalence and government support initiatives, the market will likely continue to grow.
North American region held the highest market share in the Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year
North America held the highest market share of about 62.6% in the Glucagon-like Peptide-1 (GLP-1) Agonists Market in the current year.
The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.
Health Canada is the third regulatory agency to provide more options for people interested in GLP-1 agonists. It approved the first and only GLP-1 agonist pill (Rybelsus by Novo Nordisk) for people with type 2 diabetes recently after approval by the European Medicines Agency and the US. GLP-1 RAs can be taken alone or in combination with other treatments for type 2 diabetes to improve blood glucose management, i.e., time in range. In addition to lowering blood glucose, they benefit heart health by reducing the risk of heart attack, stroke, and heart-related death. It is important because people with type 2 diabetes are at substantially higher risk of heart disease than those without diabetes.
Owing to the high prevalence of diabetes due to a sedentary lifestyle and the factors above market is expected to grow over the forecast period.
